ARTICLE | Company News

Melmed Holdings, Uluru sales and marketing update

January 23, 2012 8:00 AM UTC

Uluru finalized a deal granting Melmed's Altrazeal Trading Ltd. subsidiary exclusive rights to commercialize Altrazeal in the EU, Australia, New Zealand, North Africa and the Middle East. Uluru will receive $250,000 in licensing fees and is eligible for royalties. Uluru will supply Altrazeal at 30% of the European net sale price (see BioCentury, Dec. 19, 2011). ...